Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.
NCT ID: NCT00568945
Last Updated: 2014-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
28 participants
INTERVENTIONAL
2008-01-31
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment and Outcomes of Atrial Fibrillation and Acute Coronary Syndrome in Sweden
NCT03311139
Ventricular Tachycardia (VT) Ablation or Escalated Drug Therapy
NCT00905853
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial
NCT01288352
Totally Endoscopic Ablation of Atrial Fibrillation
NCT00940056
Impact of Catheter Ablation on ABC Risk Scores
NCT05635864
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Capadenoson (BAY68-4986)
4 mg BAY68-4986 for five days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Capadenoson (BAY68-4986)
4 mg BAY68-4986 for five days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History of persistent or permanent atrial fibrillation
* 18 to 75 years of age
Exclusion Criteria
* Stroke or myocardial infarction
* Relevant pathological changes in the ECG or echocardiography
* Medication affecting ventricular response in Afib
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Erfurt, Thuringia, Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Click here to find information about studies related to Bayer Healthcare products conducted in Europe
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007-003619-30
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
12679
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.